USA Samsung Bioepis is expanding in the US biosimilars market, with ten FDA approvals so far, seven assets in development, and an ambitious target of 20 products on the market by 2031. Tom Newcomer, SVP and Head of US Commercial, sets out why quality and supply reliability, rather than low prices,…
USA One of India’s leading pharmas is in transformation mode, with the US at the heart of it. Zydus, not content with staying in its lane as a pure-play generics player (among the top five in the US market), has been branching out over the past decade, with the aim of…
Europe Europe accounts for more than half of Sandoz’s global sales, and the company keeps reinvesting here, from biosimilar development and manufacturing in Slovenvia and France to antibiotic production in Austria. Christophe Delenta, President Europe, explains how closely Sandoz’s success is tied to Europe, how the company plans to grow its…
Korea We are building an end-to-end ecosystem that connects the journey from the laboratory to the patient within a unified value chain Dr Pyung-suk Ki has built Korean biotech ViGenCell around an integrated “lab to patient” model spanning cell therapy research, clinical development, and in-house manufacturing. Dr Ki discusses how his…
Europe 24 of the top 25 injectable drugs on the market rely on a BD component. This position puts the company at the centre of the GLP-1 boom, the coming biosimilars wave, and the shift of injectable treatment from hospitals to patients’ homes. Patrick Jeukenne, BD’s worldwide president of Pharmaceutical Systems,…
USA Generics and biosimilars serve as the financial bedrock preventing the US healthcare system from collapsing under the weight of escalating drug prices. “Generic drugs account for nearly 90 percent of all prescriptions filled in the United States, yet they consume only about 12 percent of total US prescription drug spending,”…
USA The American pharmaceutical market dominates the global landscape, accounting for nearly 50 percent of all global prescription drug sales by value. In 2024, the US market alone generated roughly USD 800 billion of the USD 1.7 trillion worldwide pharmaceutical revenue, cementing its status as the undisputed epicentre of the global…
USA A single pivotal trial can cost up to USD 150 million. A biosimilar efficacy study can take two to three years. A cell or gene therapy batch can be one patient’s only treatment. In 2026, along with several major personnel changes, the FDA moved to ease all three of these…
Korea When you establish an ecosystem where researchers can freely generate and test ideas, they can rapidly address critical real-world challenges At his lab in KAIST’s Department of Chemical and Biomolecular Engineering, Distinguished Professor Sang Yup Lee is pioneering microbial cell factory technologies to replace fossil-fuel-based manufacturing with sustainable biomanufacturing.…
Global After nearly two decades of real-world use, the safety and efficacy of biosimilars are no longer in question, yet access remains uneven worldwide. Following Global Biosimilars Week 2026, International Generic and Biosimilar Medicines Association (IGBA) Secretary General Ana Gaunt argues that the barriers are now policy and market design, and…
Korea Dr Jai Jun Choung, CEO of AriBio, discusses the company’s integrated approach to neurodegenerative disease, combining AI-driven network biology, polypharmacology and prevention to develop therapies for Alzheimer’s and related disorders. He outlines the progress of lead candidate AR1001, the broader pipeline, strategic partnerships, and Korea’s biotech ecosystem, while emphasising patient-centred…
Europe Behind every dose of heparin lies a complex industrial process in which access to raw materials, traceability and manufacturing expertise are as important as the medicine itself. Luis Solera, CEO of Bioiberica, examines how the Barcelona-based group has turned these capabilities into a global business spanning human, animal and plant…
See our Cookie Privacy Policy Here